The stock of IGM Biosciences Inc (IGMS) has gone up by 7.32% for the week, with a 23.72% rise in the past month and a -21.85% drop in the past quarter. The volatility ratio for the week is 8.06%, and the volatility levels for the past 30 days are 10.94% for IGMS. The simple moving average for the past 20 days is 15.04% for IGMS’s stock, with a 18.79% simple moving average for the past 200 days.
Is It Worth Investing in IGM Biosciences Inc (NASDAQ: IGMS) Right Now?
Company’s 36-month beta value is 0.25.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IGMS is 20.89M, and currently, short sellers hold a 25.12% ratio of that floaft. The average trading volume of IGMS on May 10, 2024 was 296.32K shares.
IGMS) stock’s latest price update
The stock price of IGM Biosciences Inc (NASDAQ: IGMS) has jumped by 8.35 compared to previous close of 9.34. Despite this, the company has seen a gain of 7.32% in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-08 that IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.33 per share a year ago.
Analysts’ Opinion of IGMS
Many brokerage firms have already submitted their reports for IGMS stocks, with RBC Capital Mkts repeating the rating for IGMS by listing it as a “Outperform.” The predicted price for IGMS in the upcoming period, according to RBC Capital Mkts is $21 based on the research report published on February 09, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see IGMS reach a price target of $8. The rating they have provided for IGMS stocks is “Neutral” according to the report published on December 15th, 2023.
H.C. Wainwright gave a rating of “Neutral” to IGMS, setting the target price at $7 in the report published on December 07th of the previous year.
IGMS Trading at 4.27% from the 50-Day Moving Average
After a stumble in the market that brought IGMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.82% of loss for the given period.
Volatility was left at 10.94%, however, over the last 30 days, the volatility rate increased by 8.06%, as shares surge +21.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.08% lower at present.
During the last 5 trading sessions, IGMS rose by +7.32%, which changed the moving average for the period of 200-days by +2.33% in comparison to the 20-day moving average, which settled at $8.89. In addition, IGM Biosciences Inc saw 21.78% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IGMS starting from BAKER BROS. ADVISORS LP, who purchase 97,473 shares at the price of $9.62 back on Mar 28 ’24. After this action, BAKER BROS. ADVISORS LP now owns 3,753,480 shares of IGM Biosciences Inc, valued at $937,632 using the latest closing price.
BAKER BROS. ADVISORS LP, the Director of IGM Biosciences Inc, purchase 27,844 shares at $9.24 during a trade that took place back on Mar 27 ’24, which means that BAKER BROS. ADVISORS LP is holding 3,664,073 shares at $257,170 based on the most recent closing price.
Stock Fundamentals for IGMS
Current profitability levels for the company are sitting at:
- -120.64 for the present operating margin
- -2.78 for the gross margin
The net margin for IGM Biosciences Inc stands at -112.55. The total capital return value is set at -0.75. Equity return is now at value -118.26, with -56.49 for asset returns.
Based on IGM Biosciences Inc (IGMS), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -4.49. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is -63.84.
Currently, EBITDA for the company is -255.18 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 265.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.98.
Conclusion
In a nutshell, IGM Biosciences Inc (IGMS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
